Related Experiment Video
Updated: Jul 21, 2026

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
Published on: January 14, 2016
Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT
F L Delarue1, J Adnane, B Joshi
1Drug Discovery Program at H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Abstract:
Recently, we have shown that RhoB suppresses EGFR-, ErbB2-, Ras- and Akt-mediated malignant transformation and metastasis. In this paper, we demonstrate that the novel antitumor agents farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs) upregulate RhoB expression in a wide spectrum of human cancer cells including those from pancreatic, breast, lung, colon, bladder and brain cancers. RhoB induction by FTI-277 and GGTI-298 occurs at the transcriptional level and is blocked by actinomycin D. Reverse transcription-PCR experiments documented that the increase in RhoB protein levels is due to an increase in RhoB transcription. Furthermore, treatment with FTIs and GGTIs of cancer cells results in HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Thus, promoter acetylation is a novel mechanism by which RhoB expression levels are regulated following treatment with the anticancer agents FTIs and GGTIs.
Insights
Novel anticancer agents, farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs), upregulate RhoB expression in various human cancers. This occurs via transcriptional regulation and promoter acetylation, offering a new therapeutic mechanism.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- RhoB protein plays a crucial role in suppressing malignant transformation and metastasis.
- EGFR, ErbB2, Ras, and Akt signaling pathways are implicated in cancer progression.
Purpose of the Study:
- To investigate the effect of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs) on RhoB expression in human cancer cells.
- To elucidate the regulatory mechanism of RhoB induction by FTIs and GGTIs.
Main Methods:
- Treatment of various human cancer cell lines (pancreatic, breast, lung, colon, bladder, brain) with FTIs (e.g., FTI-277) and GGTIs (e.g., GGTI-298).
- Analysis of RhoB expression levels using Western blotting and reverse transcription-PCR.
- Assessment of transcriptional regulation using actinomycin D.
- Chromatin immunoprecipitation assays to study histone modifications (acetylation) and protein interactions (HDAC1, HAT) at the RhoB promoter.
Main Results:
- FTIs and GGTIs significantly upregulate RhoB expression across a wide spectrum of human cancer cells.
- RhoB induction is mediated at the transcriptional level, as evidenced by increased RhoB transcription and blockage by actinomycin D.
- Anticancer agent treatment leads to dissociation of HDAC1, association of HAT, and histone acetylation of the RhoB promoter.
Conclusions:
- FTIs and GGTIs represent novel therapeutic agents that can upregulate RhoB expression in cancer cells.
- RhoB promoter acetylation is identified as a novel mechanism regulating RhoB expression in response to FTIs and GGTIs.
- Targeting RhoB expression through promoter acetylation may offer a new strategy for cancer therapy.
Related Concept Videos
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
RNA Polymerase II Accessory Proteins
Co-activators and Co-repressors
Regulation of Angiogenesis and Blood Supply
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
TGF - β Signaling Pathway

